Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Symvivo Corporation Announces Research Collaboration With Janssen
Details : Under the terms of the agreement, Janssen will have the exclusive option to research, develop and commercialize novel biological therapeutic candidates based on Symvivo’s bacTRL™ platform technology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 24, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : bacTRL-Spike Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Research Council Industrial Research Assistance Program
Deal Size : $2.8 million
Deal Type : Funding
Symvivo Corporation Receives Funding for COVID-19 Vaccine Program
Details : The funding follows a notification Symvivo received from the Government of Canada indicating it had reviewed Symvivo’s proposal and its bacTRL-Spike™ vaccine candidate had met the required scientific and technical thresholds for funding.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : bacTRL-Spike Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Research Council Industrial Research Assistance Program
Deal Size : $2.8 million
Deal Type : Funding
Lead Product(s) : bacTRL-Spike
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Symvivo to Start Safety Analysis of a COVID-19 Vaccine Candidate
Details : Symvivo disclosed it was recruiting up to 84 participants for an observed-blinded Phase I clinical trial to evaluate the safety, tolerability and immunogenicity of its bacTRL-Spike.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 05, 2020
Lead Product(s) : bacTRL-Spike
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : bacTRL-Spike Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study will evaluate safety and preliminary evidence of immunogenicity to SARS CoV-2 elicited by bacTRL-Spike™ among healthy volunteers. Preliminary data are anticipated in early 2021.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 11, 2020
Lead Product(s) : bacTRL-Spike Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable